NovaBay Pharmaceuticals Inc (NBY) - Net Assets
Based on the latest financial reports, NovaBay Pharmaceuticals Inc (NBY) has net assets worth $-22.83 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.04 Million) and total liabilities ($31.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NovaBay Pharmaceuticals Inc (NBY) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-22.83 Million |
| % of Total Assets | -252.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -324.42% |
| 10-Year Change | -421.45% |
| Growth Volatility | 325.89 |
NovaBay Pharmaceuticals Inc - Net Assets Trend (2003–2025)
This chart illustrates how NovaBay Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore NovaBay Pharmaceuticals Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for NovaBay Pharmaceuticals Inc (2003–2025)
The table below shows the annual net assets of NovaBay Pharmaceuticals Inc from 2003 to 2025. For live valuation and market cap data, see NBY company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-22.83 Million | -17594.57% |
| 2024-12-31 | $-129.00K | -103.89% |
| 2023-12-31 | $3.31 Million | -68.60% |
| 2022-12-31 | $10.55 Million | +3.77% |
| 2021-12-31 | $10.17 Million | -17.43% |
| 2020-12-31 | $12.32 Million | +1165.98% |
| 2019-12-31 | $973.00K | -80.36% |
| 2018-12-31 | $4.95 Million | +90.98% |
| 2017-12-31 | $2.59 Million | -63.47% |
| 2016-12-31 | $7.10 Million | +239.29% |
| 2015-12-31 | $-5.10 Million | -375.87% |
| 2014-12-31 | $1.85 Million | -78.30% |
| 2013-12-31 | $8.52 Million | -39.38% |
| 2012-12-31 | $14.05 Million | +50.35% |
| 2011-12-31 | $9.34 Million | -10.92% |
| 2010-12-31 | $10.49 Million | -21.39% |
| 2009-12-31 | $13.35 Million | +81.69% |
| 2008-12-31 | $7.34 Million | -48.71% |
| 2007-12-31 | $14.32 Million | +689.85% |
| 2006-12-31 | $1.81 Million | -44.25% |
| 2005-12-31 | $3.25 Million | +305.49% |
| 2003-12-31 | $802.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NovaBay Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21041500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $252.00K | % |
| Other Components | $187.34 Million | % |
| Total Equity | $-22.83 Million | 100.00% |
NovaBay Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of NovaBay Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stablecoin Development Corporation
NYSE MKT:SDEV
|
$39.41 Million |
|
Dancomech Holdings Bhd
KLSE:5276
|
$39.44 Million |
|
German High Street Properties A/S Class B
CO:GERHSP
|
$39.45 Million |
|
GBK Beteiligungen AG
HM:GBQ
|
$39.49 Million |
|
EITA Resources Bhd
KLSE:5208
|
$39.40 Million |
|
Far East Fame Line DDB Public Company Limited
BK:FE
|
$39.37 Million |
|
Career Point Limited
NSE:CAREERP
|
$39.37 Million |
|
Chi Hua Fitness Co Ltd
TWO:1593
|
$39.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NovaBay Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -129,000 to -22,826,000, a change of -22,697,000.
- Net loss of 22,141,000 reduced equity.
- Dividend payments of 4,817,000 reduced retained earnings.
- Share repurchases of 2,176,000 reduced equity.
- New share issuances of 5,835,000 increased equity.
- Other factors increased equity by 602,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.14 Million | -97.0% |
| Dividends Paid | $4.82 Million | -21.1% |
| Share Repurchases | $2.18 Million | -9.53% |
| Share Issuances | $5.83 Million | +25.56% |
| Other Changes | $602.00K | +2.64% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NovaBay Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | $34.71 | $1.48 | x |
| 2005-12-31 | $117.29 | $1.48 | x |
| 2006-12-31 | $55.52 | $1.48 | x |
| 2007-12-31 | $279.25 | $1.48 | x |
| 2008-12-31 | $301.57 | $1.48 | x |
| 2009-12-31 | $101.03 | $1.48 | x |
| 2010-12-31 | $78.70 | $1.48 | x |
| 2011-12-31 | $63.45 | $1.48 | x |
| 2012-12-31 | $83.49 | $1.48 | x |
| 2013-12-31 | $62.36 | $1.48 | x |
| 2014-12-31 | $13.53 | $1.48 | x |
| 2015-12-31 | $-64.09 | $1.48 | x |
| 2016-12-31 | $113.17 | $1.48 | x |
| 2017-12-31 | $41.47 | $1.48 | x |
| 2018-12-31 | $71.15 | $1.48 | x |
| 2019-12-31 | $11.02 | $1.48 | x |
| 2020-12-31 | $86.04 | $1.48 | x |
| 2021-12-31 | $57.09 | $1.48 | x |
| 2022-12-31 | $45.89 | $1.48 | x |
| 2023-12-31 | $5.52 | $1.48 | x |
| 2024-12-31 | $-0.01 | $1.48 | x |
| 2025-12-31 | $-3.92 | $1.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NovaBay Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-178.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | -121.82% | 0.00% | 0.00x | 1.64x | $-1.06 Million |
| 2005 | -106.49% | 0.00% | 0.00x | 1.10x | $-3.79 Million |
| 2006 | -291.56% | -344.81% | 0.13x | 6.54x | $-5.47 Million |
| 2007 | -37.71% | -91.32% | 0.25x | 1.67x | $-6.83 Million |
| 2008 | -110.47% | -120.71% | 0.48x | 1.90x | $-8.85 Million |
| 2009 | 20.21% | 17.20% | 0.90x | 1.31x | $1.36 Million |
| 2010 | -41.07% | -44.17% | 0.63x | 1.48x | $-5.36 Million |
| 2011 | -54.42% | -46.15% | 0.69x | 1.71x | $-6.02 Million |
| 2012 | -50.02% | -101.15% | 0.36x | 1.37x | $-8.43 Million |
| 2013 | -188.37% | -461.37% | 0.22x | 1.84x | $-16.89 Million |
| 2014 | -822.19% | -1441.56% | 0.14x | 4.08x | $-15.38 Million |
| 2015 | 0.00% | -433.07% | 0.86x | 0.00x | $-18.46 Million |
| 2016 | -185.20% | -110.54% | 0.77x | 2.17x | $-13.86 Million |
| 2017 | -285.39% | -40.61% | 1.81x | 3.89x | $-7.66 Million |
| 2018 | -132.12% | -52.33% | 1.34x | 1.89x | $-7.04 Million |
| 2019 | -992.60% | -146.36% | 0.59x | 11.53x | $-9.76 Million |
| 2020 | -89.62% | -111.12% | 0.65x | 1.24x | $-12.27 Million |
| 2021 | -57.26% | -57.08% | 0.43x | 2.36x | $-6.84 Million |
| 2022 | -100.51% | -73.65% | 0.88x | 1.55x | $-11.66 Million |
| 2023 | -290.89% | -92.20% | 1.16x | 2.73x | $-9.97 Million |
| 2024 | 0.00% | -73.85% | 2.86x | 0.00x | $-7.21 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.86 Million |
Industry Comparison
This section compares NovaBay Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NovaBay Pharmaceuticals Inc (NBY) | $-22.83 Million | -121.82% | N/A | $39.41 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. T… Read more